The hospital line marketing department is the theater line marketing department under the Microdiag, dedicated to creating a new marketing model for the three major theater lines (Suzhou Huajian, Weizhenbio, and Beijing Quick). The hospital line marketing department was established in 2021 and is located in Building 16, Northwest District, Suzhou Nano City, No. 99, Jinjihu Avenue, Suzhou Industrial Park. As a dynamic and innovative marketing team, it is currently mainly responsible for operating the company's four new tumor markers that have been approved for marketing:

① The only internationally recognized new indicator for early detection of pan-cancer - DR-70 quantitative detection kit;

②New molecular indicator for colorectal cancer blood test - Septin9 gene methylation detection kit;

③The world's exclusive new tumor marker for gastrointestinal cancer - CST4 quantitative detection kit;

④ Liver injury direct biomarkers - sH2a quantitative detection kit, etc.

The hospital line marketing department will focus on the theater line marketing, academic activities, brand promotion, the construction of national model hospitals, and the establishment of KOL team public relations, etc., to gradually improve the company's brand awareness, increase the stickiness of clinical experts and enterprises, and achieve better Products serve clinical trials, and more customers can achieve patent conversion.

In line with the purpose of strengthening brand building, popularizing new tumor markers in more hospitals and benefiting more patients, we will continue to work hard in the field of early tumor detection, and provide the most professional and high-quality services.